Fisetin for COVID-19 (COVID-FIS Trial)

Palo Alto (17 mi)

Overseen byBrandon P Verdoorn, MD

Age: 65+

Sex: Any

Travel: May be covered

Time Reimbursement: Varies

Trial Phase: Phase 2

Waitlist Available

Sponsor: Mayo Clinic

Prior Safety Data

Trial Summary

What is the purpose of this trial?The purpose of this study is to test whether Fisetin, a senolytic drug, can assist in preventing an increase in the disease's progression and alleviate complications of coronavirus due to an excessive inflammatory reaction.

Eligibility Criteria

This trial is for nursing home residents aged 65 or older who have moderate or less severe COVID-19, confirmed by a PCR test within the last 10 days. Participants must be able to consent and have functioning major organs. Those with certain severe health conditions, participating in other COVID-19 treatment trials, or with allergies to Fisetin are excluded.

Inclusion Criteria

My COVID-19 symptoms are moderate or less, or my oxygen levels are 85% or higher.

I currently live in a nursing home.

I am a man or a post-menopausal woman aged 65 or older.

Exclusion Criteria

I have an invasive fungal infection.

I am post-menopausal and not pregnant.

I am HIV positive.

Treatment Details

The study is testing if Fisetin can prevent worsening of COVID-19 symptoms and reduce complications from excessive inflammation. It's a pilot study where participants will either receive Fisetin or a placebo without knowing which one they're getting.

2Treatment groups

Experimental Treatment

Placebo Group

Group I: Treatment GroupExperimental Treatment1 Intervention

Subjects will receive treatment drug (Fisetin)

Group II: Placebo GroupPlacebo Group1 Intervention

Subjects will receive placebo